01

Who we are

02

MyGeneraTM

03

Product Pipeline

04

Research & Innovation

05

Partnership

06

News & Media

Biogenera at Swiss Biotech Day 2025: Innovation and International Dialogue

Biogenera participated in the Swiss Biotech Day 2025, one of Europe’s most prominent events in the biotechnology sector, held on May 5–6 at the Congress Center in Basel.

It was a strategic occasion to strengthen our international relationships, present our ongoing R&D programs, and engage in meaningful exchanges with key players in the global pharma-biotech landscape.

Institutional Presence

Biogenera was represented by Massimiliano Cesarini (CEO & Chairman) and Federico Ragni (Head of Business Development), who took part in one-to-one partnering meetings, industry roundtables, and extensive networking opportunities.

Our team introduced the progress of our proprietary MyGenera™ platform, based on anti-gene oligonucleotides using Peptide Nucleic Acid (PNA) technology, and showcased the clinical development of BGA002, the world’s first drug candidate targeting the MYCN oncogene, a key driver in aggressive pediatric and adult cancers.

Partnership and Vision

Swiss Biotech Day offered a unique opportunity to:

  • Consolidate scientific and industrial partnerships
  • Gather feedback from international experts
  • Explore licensing and co-development opportunities
  • Strengthen Biogenera’s visibility within leading European biotech ecosystems

Looking Ahead

Participating in high-level events like the Swiss Biotech Day reflects our commitment to advancing transformative science and making it accessible to those who need it most. As we approach the Phase I clinical trial of BGA002, Biogenera continues to engage with global partners to accelerate the delivery of breakthrough therapies.

en_USEnglish